Identification of antigenic peptides from multiple myeloma...

Details Identification of antigenic peptides from multiple myeloma... Identification of antigenic peptides from multiple myeloma...

2009-09-22

2011-12-13

Belyavskyi, Michail (Department: 1644)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C530S300000

Reexamination Certificate

active

08075895

ABSTRACT:
Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.

REFERENCES:
patent: 4690915 (1987-09-01), Rosenberg
patent: 4844893 (1989-07-01), Honsik et al.
patent: 5126132 (1992-06-01), Rosenberg
patent: 5443983 (1995-08-01), Ochoa et al.
patent: 5766920 (1998-06-01), Babbitt
patent: 5846827 (1998-12-01), Celis et al.
patent: 6040177 (2000-03-01), Riddell et al.
patent: 6194207 (2001-02-01), Bell
patent: 6225042 (2001-05-01), Cai et al.
patent: 6251385 (2001-06-01), Terman
patent: 6255073 (2001-07-01), Cai et al.
patent: 6355479 (2002-03-01), Webb et al.
patent: 6362001 (2002-03-01), Cai et al.
patent: 6790662 (2004-09-01), Leturcq
patent: 7402314 (2008-07-01), Sherman
patent: 2002/0119121 (2002-08-01), Vitiello et al.
patent: 2007/0258959 (2007-11-01), Schuler et al.
patent: 2009/0004142 (2009-01-01), Leturcq et al.
patent: 2009/0010950 (2009-01-01), Roncarolo et al.
patent: 2009/0017000 (2009-01-01), Cai et al.
patent: WO 02/22648 (2002-03-01), None
patent: WO 2007/103009 (2007-09-01), None
Andersen et al.,Tissue Antigens. 54(2):185-90 (1999).
Baccala et al.,J. Immunol., vol. 174, pp. 4606-4612 (2005).
Brunner et al.,Immunology. 14(2):181-96 (1968).
Carter et al.,Curr. Opin. Immunol., vol. 8(3), pp. 336-342 (1996).
Cerwenka et al., J.Immunol., vol. 163(10), pp. 5535-5543 (1999).
Cerwenka et al., J.Immunol., vol. 161, pp. 97-105 (1998).
Croft et al., J. Exp. Med., vol. 180, pp. 1715-1728 (1994).
Dudley ME, et al,Science. 298(5594):850-4 (2002).
Fujihashi et al., Proc. Natl. Acad. Sci. USA, vol. 93, pp. 3613-3618 (1996).
Goldrath et al.,J. Exp. Med., vol. 192, pp. 557-564 (2000).
Ishimaru et al.,Nature Immunol., vol. 7(7), pp. 763-772 (2006).
Kaech et al.,Cell, vol. 111, pp. 837-851 (2002).
Kern et al.,Eur. J. Immunol., vol. 29, pp. 2908-2915 (1999).
Kieper et al.,J. Immunol., vol. 174, pp. 3158-3163 (2005).
Kieper et al.,Proc. Natl. Acad. Sci. USA, vol. 96, pp. 13306-13311 (1999).
Kyle RA and Rajkumar SV. ,N. Engl J Med.351(18):1860-73 (2004).
Livingston et al., Immunol. Invest., vol. 24(4), pp. 619-629 (1995).
Lu et al.,Cancer Immunol Immunother. 58(4):629-38 (2009).
McFarland et al.,PNAS, vol. 97(8), pp. 4215-4220 (2000).
Mosmann et al.,Immunol. Today, vol. 17(3), pp. 138-146 (1996).
Münz et al.,J Immunol. 162(1):25-34 (1999).
Murali-Krishna et al.,J. Immunol., vol. 165, pp. 1733-1737 (2000).
Opferman et al.,Science, vol. 283, pp. 1745-1748 (1999).
Parham and Brodsky,Hum Immunol. 3(4):277-99 (1981).
Parker et al.,J Immunol.149(11):3580-7 (1992).
Parkhurst MR, et al,J Immunol.157(6):2539-48 (1996).
Rosenberg SA, et al,Nat Med.4(3):321-7 (1998).
Sad et al.,Immunity, vol. 2, pp. 271-279 (1995).
Sadovnikova et al.,Eur J Immunol. 28(1):193-200 (1998).
Schneider,J. Embryol. Exp. Morph. vol. 27, pp. 353-365 (1972).
Townsend et al.,Cell.62(2):285-95 (1990).
Walzer et al., Cell.Immunol., vol. 206, pp. 16-25 (2000).
Wherry et al.,Nat. Immunol., vol. 4, pp. 225-234 (2003).
Yee C, et al,Proc Natl Acad Sci U S A. 99(25):16168-73 (2002).
Zhang et al.Immunology. 121(1):105-12 (2007).

Affiliated with

Also associated with

Rating

Identification of antigenic peptides from multiple myeloma... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Identification of antigenic peptides from multiple myeloma..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identification of antigenic peptides from multiple myeloma... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4311891